[go: up one dir, main page]

ES2062079T3 - Medicamento para el tratamiento o la prevencion por inmunizacion pasiva de la infeccion por el virus hiv y procedimientos de preparacion. - Google Patents

Medicamento para el tratamiento o la prevencion por inmunizacion pasiva de la infeccion por el virus hiv y procedimientos de preparacion.

Info

Publication number
ES2062079T3
ES2062079T3 ES89403495T ES89403495T ES2062079T3 ES 2062079 T3 ES2062079 T3 ES 2062079T3 ES 89403495 T ES89403495 T ES 89403495T ES 89403495 T ES89403495 T ES 89403495T ES 2062079 T3 ES2062079 T3 ES 2062079T3
Authority
ES
Spain
Prior art keywords
prevention
treatment
medication
passive immunization
hiv virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES89403495T
Other languages
English (en)
Inventor
Michel Grandgeorge
Francois Pelloquin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Pasteur SA
Original Assignee
Pasteur Merieux Serum et Vaccines SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Merieux Serum et Vaccines SA filed Critical Pasteur Merieux Serum et Vaccines SA
Application granted granted Critical
Publication of ES2062079T3 publication Critical patent/ES2062079T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

EL MEDICAMENTO SEGUN LA INVENCION ESTA CONSTITUIDO POR, O COMPRENDE, UNA PREPARACION DE GAMMAGLOBULINAS IGG Y/O IGM DE ORIGEN HUMANO ANTI-HIV DESPROVISTA DE ANTICUERPOS DIRIGIDOS CONTRA LAS GLICOPROTEINAS DE REVESTIMIENTO DEL VIRUS HIV Y/O ANTICUERPOS ANTI-CD4.
ES89403495T 1988-12-15 1989-12-15 Medicamento para el tratamiento o la prevencion por inmunizacion pasiva de la infeccion por el virus hiv y procedimientos de preparacion. Expired - Lifetime ES2062079T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8816580A FR2640511B1 (fr) 1988-12-15 1988-12-15 Medicaments pour le traitement ou la prevention par immunisation passive de l'infection par le virus hiv et procede de preparation

Publications (1)

Publication Number Publication Date
ES2062079T3 true ES2062079T3 (es) 1994-12-16

Family

ID=9373004

Family Applications (1)

Application Number Title Priority Date Filing Date
ES89403495T Expired - Lifetime ES2062079T3 (es) 1988-12-15 1989-12-15 Medicamento para el tratamiento o la prevencion por inmunizacion pasiva de la infeccion por el virus hiv y procedimientos de preparacion.

Country Status (13)

Country Link
EP (1) EP0374053B1 (es)
JP (1) JPH03505738A (es)
CN (1) CN1045035A (es)
AT (1) ATE102836T1 (es)
AU (1) AU627540B2 (es)
CA (1) CA2005365C (es)
DE (1) DE68913932T2 (es)
DK (1) DK192990A (es)
ES (1) ES2062079T3 (es)
FR (1) FR2640511B1 (es)
IE (1) IE63831B1 (es)
WO (1) WO1990006773A1 (es)
ZA (1) ZA899533B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0686260B1 (en) * 1993-02-05 2003-07-09 Epigen, Inc. Human carcinoma antigen (hca), hca antibodies, hca immunoassays, methods of imaging and therapy
CN106110422B (zh) * 2016-07-01 2019-02-01 翁炳焕 艾滋病免疫治疗吸附器

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3604947A1 (de) * 1986-02-17 1987-08-20 Biotest Pharma Gmbh Verfahren zur herstellung eines immunglobulinhaltigen praeparates und dessen verwendung zur prophylaxe und therapie von aids
US4863730A (en) * 1986-03-21 1989-09-05 Cenfold Holdings, S.A. Immunotherapy for AIDS patients
AU618555B2 (en) * 1987-08-11 1992-01-02 Biomune Corporation Hyper-immune globulin against hiv

Also Published As

Publication number Publication date
DK192990D0 (da) 1990-08-14
CN1045035A (zh) 1990-09-05
DE68913932T2 (de) 1994-07-07
AU627540B2 (en) 1992-08-27
IE894005L (en) 1990-06-15
IE63831B1 (en) 1995-06-14
FR2640511B1 (fr) 1993-04-23
JPH03505738A (ja) 1991-12-12
ZA899533B (en) 1990-12-28
EP0374053A1 (fr) 1990-06-20
WO1990006773A1 (fr) 1990-06-28
AU4806290A (en) 1990-07-10
DE68913932D1 (de) 1994-04-21
CA2005365C (en) 1995-12-12
CA2005365A1 (en) 1990-06-15
EP0374053B1 (fr) 1994-03-16
ATE102836T1 (de) 1994-04-15
DK192990A (da) 1990-08-14
FR2640511A1 (fr) 1990-06-22

Similar Documents

Publication Publication Date Title
EP0429477A4 (en) Synthetic vaccine against aids virus
BR9712289A (pt) Composições e métodos para o tratamento de infecções virais
ES2187530T3 (es) Peptidos para reducir respuestas de linfocito t ctitotoxicos al virus de la hepatitis b.
CA2192512A1 (en) Nm03 antibody materials and methods
EP0687182A4 (en) PEPTIDES FOR INDUCING A RESPONSE OF THE CYTOTOXIC T-LYMPHOCYTES AGAINST THE HEPATITIS B VIRUS
HUP9801266A2 (hu) Multimer, rekombináns ureázvakcina
ATE78696T1 (de) Arzneimittelzubereitung zur behandlung des immunmangels.
FI944561L (fi) HIV:tä neutraloivia monoklonaalisia yhdistelmähumaanivasta-aineita HIV-infektion ehkäisemiseksi ja hoitamiseksi
SE9000333D0 (sv) Monoklonal antikropp
DK322287A (da) Mod infektioner af pseudomonas aeruginosa virksomme praeparater og fremgangsmaade til fremstilling deraf
ES2062079T3 (es) Medicamento para el tratamiento o la prevencion por inmunizacion pasiva de la infeccion por el virus hiv y procedimientos de preparacion.
DK0516135T3 (da) Humant immundefektvirus-relateret immunpræparat
DE69433789D1 (de) Methoden zur inhibition von hiv-assotiierte krankheit mittels monoklonaler antikörper gegen sich selbstgerichtete zytotoxische t-zellen
DK56389D0 (da) Forhindring og behandling af retroviralt frembragte sygdomme
ATE108335T1 (de) Kit oder zusammensetzung zur vorbeugung oder behandlung von hiv-1 infektionen.
KR950702838A (ko) 인터루킨-4(IL-4)를 사용한 사람 면역결핍 바이러스(HIV) 복제의 억제방법(Method for inhibiting HIV replication using IL-4)
CA2160696A1 (en) Peptides for use in vaccination and induction of neutralizing antibodies against human immunodeficiency virus
ATE128733T1 (de) Monoklonale antikörper gegen hiv gp120.
FR2614025B1 (fr) Peptides susceptibles d'etre reconnus par des anticorps induits contre des retrovirus d'immunodeficience humaine (virus hiv) leurs applications au diagnostic des infections dues a certains de ces virus et, le cas echeant, a la vaccination contre le sida
FI930519A7 (fi) Peptiidejä HIV-viruksen aiheuttaman infektion torjumiseksi sekä menete lmä niiden käyttämiseksi
ES2076526T3 (es) Antagonistas de bcrf1 para tratar infecciones del virus epstein-barr.
DK0470989T3 (da) Anvendelse af monoklonale anti-beta2 mikroglobulin antistoffer
WO1988008707A3 (en) Rubradirin derivatives for treatment of hiv infection

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 374053

Country of ref document: ES